13D Filing: Novo A/s and Htg Molecular Diagnostics Inc (NASDAQ:HTGM)

This amendment (Amendment No. 2) amends the Schedule 13D originally filed with the
Commission on May 13, 2015, as subsequently amended by Amendment No. 1 filed with the Commission on March 10, 2017 (the Schedule), to report a decrease in the beneficial ownership percentage of the Reporting Person
resulting from an increase in the Issuers Common Stock outstanding. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.

Item 5(a) of the Schedule is amended and replaced in its
entirety as follows:

(a) Novo A/S beneficially owns 1,280,185 shares (the Novo Shares) of Common Stock representing
approximately 15.9% of the Issuers outstanding Common Stock, based upon 8,052,451 shares of the Issuers Common Stock outstanding on March 17, 2017 as reported in the Issuers Annual Report on Form 10-K filed with the Commission
on March 23, 2017.

3